Global (United States, European Union and China) Hepatitis B Vaccines research

Hepatitis B Vaccines Comprehensive Study by Type (Mono Vaccines, Combination Vaccines), Application (Hospitals, Retail Pharmacy, Online Pharmacy), Vaccine Type (Recombinant Vaccine, Inactivated Vaccine), Indication (Hepatitis A, Hepatitis B) Players and Region - Global Market Outlook to 2030

Hepatitis B Vaccines Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Hepatitis B Vaccines Market Overview:
Hepatitis B refers to a communicable disease that's caused by the hepatitis b virus. Symptoms of this disease are not visible within the initial stages and develop when few weeks only. Hepatitis b virus is transmitted by exposure to infectious blood or body fluids of an infected person. This sickness could even occur from birth. Hepatitis b could also be caused by blood transfusions, attention settings, sharing razors, and chemical analysis. Hepatitis b vaccine refers to a vaccine that's developed for the interference of hepatitis b viral infection. Hepatitis b vaccine consists of infective agent envelope proteins and hepatitis b surface antigens (HBsAg). Hepatitis b vaccine is created by exploiting yeast cells. As per latest study released by AMA Research, the Global Hepatitis B Vaccines market is expected to see growth rate of 5.6%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Different Variants of The Vaccine

Market Growth Drivers:
Increasing Prevalence of Hepatitis B Infection Cases, Improved Healthcare Facilities and More Awareness Among the People

Challenges:
Presence Of Competitors and Less Availability in The Developing Regions

Restraints:
High Cost of The Vaccine

Opportunities:
Government Initiatives, Growing Demographics and Economies in The Developing Countries and Increased Research and Development

Competitive Landscape:
The hepatitis vaccine market has risen in a number of cases in the hepatitis B virus is anticipated to drive the market growth. However, due to highly expensive medicine, it is restraining the hepatitis vaccine market. Moreover, the rise in the awareness of hepatitis infection prevention among people, coupled with numerous governments across the globe rolling out hepatitis immunization schedules, are the factors driving the market growth.
Some of the key players profiled in the report are Merck (Germany), GlaxoSmithKline (United Kingdom), Sanofi Pasteur (France), Human Biologicals Institute (India), Dynavax Technologies (United States), LG Life Sciences (South Korea) and Janssen Pharmaceuticals (Belgium).. Analyst at AMA Research see United States Players to retain maximum share of Global Hepatitis B Vaccines market by 2030. Considering Market by Vaccine Type, the sub-segment i.e. Recombinant Vaccine will boost the Hepatitis B Vaccines market. Considering Market by Indication, the sub-segment i.e. Hepatitis A will boost the Hepatitis B Vaccines market.

Latest Market Insights:
In July 2022, Serum Institute of India partnered with the Global Alliance for Vaccines and Immunization (GAVI) to supply affordable hepatitis B vaccines to low- and middle-income countries.

In February 2022, Merck & Co. announced its acquisition of Themis Bioscience, a biotechnology company developing a next-generation hepatitis B vaccine.

What Can be Explored with the Hepatitis B Vaccines Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hepatitis B Vaccines Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hepatitis B Vaccines
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hepatitis B Vaccines market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hepatitis B Vaccines market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Hepatitis B Vaccines, Suppliers and distributors of Hepatitis B Vaccines, Governmental and Regulatory bodies and End-Users.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Mono Vaccines
  • Combination Vaccines
By Application
  • Hospitals
  • Retail Pharmacy
  • Online Pharmacy
By Vaccine Type
  • Recombinant Vaccine
  • Inactivated Vaccine

By Indication
  • Hepatitis A
  • Hepatitis B

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Hepatitis B Infection Cases
      • 3.2.2. Improved Healthcare Facilities
      • 3.2.3. More Awareness Among the People
    • 3.3. Market Challenges
      • 3.3.1. Presence Of Competitors
      • 3.3.2. Less Availability in The Developing Regions
    • 3.4. Market Trends
      • 3.4.1. Different Variants of The Vaccine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hepatitis B Vaccines, by Type, Application, Vaccine Type, Indication and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hepatitis B Vaccines (Value)
      • 5.2.1. Global Hepatitis B Vaccines by: Type (Value)
        • 5.2.1.1. Mono Vaccines
        • 5.2.1.2. Combination Vaccines
      • 5.2.2. Global Hepatitis B Vaccines by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Hepatitis B Vaccines by: Vaccine Type (Value)
        • 5.2.3.1. Recombinant Vaccine
        • 5.2.3.2. Inactivated Vaccine
      • 5.2.4. Global Hepatitis B Vaccines by: Indication (Value)
        • 5.2.4.1. Hepatitis A
        • 5.2.4.2. Hepatitis B
      • 5.2.5. Global Hepatitis B Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Hepatitis B Vaccines (Price)
      • 5.3.1. Global Hepatitis B Vaccines by: Type (Price)
  • 6. Hepatitis B Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi Pasteur (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Human Biologicals Institute (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Dynavax Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. LG Life Sciences (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Janssen Pharmaceuticals (Belgium).
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Hepatitis B Vaccines Sale, by Type, Application, Vaccine Type, Indication and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hepatitis B Vaccines (Value)
      • 7.2.1. Global Hepatitis B Vaccines by: Type (Value)
        • 7.2.1.1. Mono Vaccines
        • 7.2.1.2. Combination Vaccines
      • 7.2.2. Global Hepatitis B Vaccines by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Hepatitis B Vaccines by: Vaccine Type (Value)
        • 7.2.3.1. Recombinant Vaccine
        • 7.2.3.2. Inactivated Vaccine
      • 7.2.4. Global Hepatitis B Vaccines by: Indication (Value)
        • 7.2.4.1. Hepatitis A
        • 7.2.4.2. Hepatitis B
      • 7.2.5. Global Hepatitis B Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Hepatitis B Vaccines (Price)
      • 7.3.1. Global Hepatitis B Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hepatitis B Vaccines: by Type(USD Million)
  • Table 2. Hepatitis B Vaccines Mono Vaccines , by Region USD Million (2018-2023)
  • Table 3. Hepatitis B Vaccines Combination Vaccines , by Region USD Million (2018-2023)
  • Table 4. Hepatitis B Vaccines: by Application(USD Million)
  • Table 5. Hepatitis B Vaccines Hospitals , by Region USD Million (2018-2023)
  • Table 6. Hepatitis B Vaccines Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 7. Hepatitis B Vaccines Online Pharmacy , by Region USD Million (2018-2023)
  • Table 8. Hepatitis B Vaccines: by Vaccine Type(USD Million)
  • Table 9. Hepatitis B Vaccines Recombinant Vaccine , by Region USD Million (2018-2023)
  • Table 10. Hepatitis B Vaccines Inactivated Vaccine , by Region USD Million (2018-2023)
  • Table 11. Hepatitis B Vaccines: by Indication(USD Million)
  • Table 12. Hepatitis B Vaccines Hepatitis A , by Region USD Million (2018-2023)
  • Table 13. Hepatitis B Vaccines Hepatitis B , by Region USD Million (2018-2023)
  • Table 14. South America Hepatitis B Vaccines, by Country USD Million (2018-2023)
  • Table 15. South America Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 16. South America Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 17. South America Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 18. South America Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 19. Brazil Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 20. Brazil Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 21. Brazil Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 22. Brazil Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 23. Argentina Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 24. Argentina Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 25. Argentina Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 26. Argentina Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 27. Rest of South America Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 30. Rest of South America Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 31. Asia Pacific Hepatitis B Vaccines, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 35. Asia Pacific Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 36. China Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 37. China Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 38. China Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 39. China Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 40. Japan Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 41. Japan Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 42. Japan Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 43. Japan Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 44. India Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 45. India Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 46. India Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 47. India Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 48. South Korea Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 49. South Korea Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 50. South Korea Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 51. South Korea Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 52. Taiwan Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 53. Taiwan Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 54. Taiwan Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 55. Taiwan Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 56. Australia Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 57. Australia Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 58. Australia Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 59. Australia Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 64. Europe Hepatitis B Vaccines, by Country USD Million (2018-2023)
  • Table 65. Europe Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 66. Europe Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 67. Europe Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 68. Europe Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 69. Germany Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 70. Germany Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 71. Germany Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 72. Germany Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 73. France Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 74. France Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 75. France Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 76. France Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 77. Italy Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 78. Italy Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 79. Italy Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 80. Italy Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 81. United Kingdom Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 82. United Kingdom Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 83. United Kingdom Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 84. United Kingdom Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 85. Netherlands Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 86. Netherlands Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 87. Netherlands Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 88. Netherlands Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 89. Rest of Europe Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 90. Rest of Europe Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 91. Rest of Europe Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 92. Rest of Europe Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 93. MEA Hepatitis B Vaccines, by Country USD Million (2018-2023)
  • Table 94. MEA Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 95. MEA Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 96. MEA Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 97. MEA Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 98. Middle East Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 99. Middle East Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 100. Middle East Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 101. Middle East Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 102. Africa Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 103. Africa Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 104. Africa Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 105. Africa Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 106. North America Hepatitis B Vaccines, by Country USD Million (2018-2023)
  • Table 107. North America Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 108. North America Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 109. North America Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 110. North America Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 111. United States Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 112. United States Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 113. United States Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 114. United States Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 115. Canada Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 116. Canada Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 117. Canada Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 118. Canada Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 119. Mexico Hepatitis B Vaccines, by Type USD Million (2018-2023)
  • Table 120. Mexico Hepatitis B Vaccines, by Application USD Million (2018-2023)
  • Table 121. Mexico Hepatitis B Vaccines, by Vaccine Type USD Million (2018-2023)
  • Table 122. Mexico Hepatitis B Vaccines, by Indication USD Million (2018-2023)
  • Table 123. Hepatitis B Vaccines: by Type(USD/Units)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Hepatitis B Vaccines: by Type(USD Million)
  • Table 132. Hepatitis B Vaccines Mono Vaccines , by Region USD Million (2025-2030)
  • Table 133. Hepatitis B Vaccines Combination Vaccines , by Region USD Million (2025-2030)
  • Table 134. Hepatitis B Vaccines: by Application(USD Million)
  • Table 135. Hepatitis B Vaccines Hospitals , by Region USD Million (2025-2030)
  • Table 136. Hepatitis B Vaccines Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 137. Hepatitis B Vaccines Online Pharmacy , by Region USD Million (2025-2030)
  • Table 138. Hepatitis B Vaccines: by Vaccine Type(USD Million)
  • Table 139. Hepatitis B Vaccines Recombinant Vaccine , by Region USD Million (2025-2030)
  • Table 140. Hepatitis B Vaccines Inactivated Vaccine , by Region USD Million (2025-2030)
  • Table 141. Hepatitis B Vaccines: by Indication(USD Million)
  • Table 142. Hepatitis B Vaccines Hepatitis A , by Region USD Million (2025-2030)
  • Table 143. Hepatitis B Vaccines Hepatitis B , by Region USD Million (2025-2030)
  • Table 144. South America Hepatitis B Vaccines, by Country USD Million (2025-2030)
  • Table 145. South America Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 146. South America Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 147. South America Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 148. South America Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 149. Brazil Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 150. Brazil Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 151. Brazil Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 152. Brazil Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 153. Argentina Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 154. Argentina Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 155. Argentina Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 156. Argentina Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 157. Rest of South America Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 158. Rest of South America Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 159. Rest of South America Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 160. Rest of South America Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 161. Asia Pacific Hepatitis B Vaccines, by Country USD Million (2025-2030)
  • Table 162. Asia Pacific Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 163. Asia Pacific Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 164. Asia Pacific Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 165. Asia Pacific Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 166. China Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 167. China Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 168. China Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 169. China Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 170. Japan Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 171. Japan Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 172. Japan Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 173. Japan Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 174. India Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 175. India Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 176. India Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 177. India Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 178. South Korea Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 179. South Korea Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 180. South Korea Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 181. South Korea Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 182. Taiwan Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 183. Taiwan Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 184. Taiwan Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 185. Taiwan Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 186. Australia Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 187. Australia Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 188. Australia Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 189. Australia Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 190. Rest of Asia-Pacific Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 191. Rest of Asia-Pacific Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 194. Europe Hepatitis B Vaccines, by Country USD Million (2025-2030)
  • Table 195. Europe Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 196. Europe Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 197. Europe Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 198. Europe Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 199. Germany Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 200. Germany Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 201. Germany Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 202. Germany Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 203. France Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 204. France Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 205. France Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 206. France Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 207. Italy Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 208. Italy Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 209. Italy Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 210. Italy Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 211. United Kingdom Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 212. United Kingdom Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 213. United Kingdom Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 214. United Kingdom Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 215. Netherlands Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 216. Netherlands Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 217. Netherlands Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 218. Netherlands Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 219. Rest of Europe Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 220. Rest of Europe Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 221. Rest of Europe Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 222. Rest of Europe Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 223. MEA Hepatitis B Vaccines, by Country USD Million (2025-2030)
  • Table 224. MEA Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 225. MEA Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 226. MEA Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 227. MEA Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 228. Middle East Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 229. Middle East Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 230. Middle East Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 231. Middle East Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 232. Africa Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 233. Africa Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 234. Africa Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 235. Africa Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 236. North America Hepatitis B Vaccines, by Country USD Million (2025-2030)
  • Table 237. North America Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 238. North America Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 239. North America Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 240. North America Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 241. United States Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 242. United States Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 243. United States Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 244. United States Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 245. Canada Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 246. Canada Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 247. Canada Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 248. Canada Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 249. Mexico Hepatitis B Vaccines, by Type USD Million (2025-2030)
  • Table 250. Mexico Hepatitis B Vaccines, by Application USD Million (2025-2030)
  • Table 251. Mexico Hepatitis B Vaccines, by Vaccine Type USD Million (2025-2030)
  • Table 252. Mexico Hepatitis B Vaccines, by Indication USD Million (2025-2030)
  • Table 253. Hepatitis B Vaccines: by Type(USD/Units)
  • Table 254. Research Programs/Design for This Report
  • Table 255. Key Data Information from Secondary Sources
  • Table 256. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hepatitis B Vaccines: by Type USD Million (2018-2023)
  • Figure 5. Global Hepatitis B Vaccines: by Application USD Million (2018-2023)
  • Figure 6. Global Hepatitis B Vaccines: by Vaccine Type USD Million (2018-2023)
  • Figure 7. Global Hepatitis B Vaccines: by Indication USD Million (2018-2023)
  • Figure 8. South America Hepatitis B Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Hepatitis B Vaccines Share (%), by Country
  • Figure 10. Europe Hepatitis B Vaccines Share (%), by Country
  • Figure 11. MEA Hepatitis B Vaccines Share (%), by Country
  • Figure 12. North America Hepatitis B Vaccines Share (%), by Country
  • Figure 13. Global Hepatitis B Vaccines: by Type USD/Units (2018-2023)
  • Figure 14. Global Hepatitis B Vaccines share by Players 2023 (%)
  • Figure 15. Global Hepatitis B Vaccines share by Players (Top 3) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck (Germany) Revenue: by Geography 2023
  • Figure 19. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 22. Sanofi Pasteur (France) Revenue: by Geography 2023
  • Figure 23. Human Biologicals Institute (India) Revenue, Net Income and Gross profit
  • Figure 24. Human Biologicals Institute (India) Revenue: by Geography 2023
  • Figure 25. Dynavax Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 26. Dynavax Technologies (United States) Revenue: by Geography 2023
  • Figure 27. LG Life Sciences (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. LG Life Sciences (South Korea) Revenue: by Geography 2023
  • Figure 29. Janssen Pharmaceuticals (Belgium). Revenue, Net Income and Gross profit
  • Figure 30. Janssen Pharmaceuticals (Belgium). Revenue: by Geography 2023
  • Figure 31. Global Hepatitis B Vaccines: by Type USD Million (2025-2030)
  • Figure 32. Global Hepatitis B Vaccines: by Application USD Million (2025-2030)
  • Figure 33. Global Hepatitis B Vaccines: by Vaccine Type USD Million (2025-2030)
  • Figure 34. Global Hepatitis B Vaccines: by Indication USD Million (2025-2030)
  • Figure 35. South America Hepatitis B Vaccines Share (%), by Country
  • Figure 36. Asia Pacific Hepatitis B Vaccines Share (%), by Country
  • Figure 37. Europe Hepatitis B Vaccines Share (%), by Country
  • Figure 38. MEA Hepatitis B Vaccines Share (%), by Country
  • Figure 39. North America Hepatitis B Vaccines Share (%), by Country
  • Figure 40. Global Hepatitis B Vaccines: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck (Germany)
  • GlaxoSmithKline (United Kingdom)
  • Sanofi Pasteur (France)
  • Human Biologicals Institute (India)
  • Dynavax Technologies (United States)
  • LG Life Sciences (South Korea)
  • Janssen Pharmaceuticals (Belgium).
Select User Access Type

Key Highlights of Report


Mar 2024 215 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Hepatitis B Vaccines research Quantitative research analysis
Global (United States, European Union and China) Hepatitis B Vaccines research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Hepatitis B Vaccines market are Merck (Germany), GlaxoSmithKline (United Kingdom), Sanofi Pasteur (France), Human Biologicals Institute (India), Dynavax Technologies (United States), LG Life Sciences (South Korea) and Janssen Pharmaceuticals (Belgium)., to name a few.
"Different Variants of The Vaccine" is seen as one of major influencing trends for Hepatitis B Vaccines Market during projected period 2023-2030.
Mono Vaccines segment in Global market to hold robust market share owing to "Increasing Prevalence of Hepatitis B Infection Cases ".

Know More About Global (United States, European Union and China) Hepatitis B Vaccines research Report?

Have a Query? Click Here

Other Related Reports

Kidney Dialysis Equipment and Supplies Comprehensive Study by Type (Hemodialysis, Peritoneal Dialysis), Application (Hospital, Clinic, Research Center, Others), Distribution Channel (Direct Tenders, ...
$ 3450
PVP Iodine Comprehensive Study by Type (Medical Grade, Industrial Grade), Application (Medical Use, Food Industry, Breed Industry, Other), End Use (Skin sterilization, Infection prevention, Instrumen...
$ 3350
Dental Restorative Materials Comprehensive Study by Type (Dental Amalgams, Dental Cements, Dental Ceramics, Dental Liners), Application (Prosthodontics, Periodontics, Endodontics, Others), Material (...
$ 3650
Non Woven Face Masks Comprehensive Study by Type (1 Ply, 2 Ply, 3 Ply), Application (Hospitals, Dental, Clean Room, Food Preparation, Industrial Environment), Size (XL), Sales Channel (Hypermarket/Su...
$ 3450
Meal Fibers Comprehensive Study by Type (Soluble Fiber, Insoluble Fiber), Application (Functional Food & Beverages, Animal Feed, Pharmaceuticals, Other) Players and Region - Global Market Outlook to ...
$ 3500
Clinical Trial Supplies Comprehensive Study by Type (Manufacturing, Packaging and Labeling, Logistics and Distribution (Cold chain based, Non-cold chain based)), Application (CNS & Mental Disorders, ...
$ 3750